Browsing Tag
Sobi
6 posts
EMBRACE results prompt Sobi to engage regulators on emapalumab sepsis pathway
Sobi will advance emapalumab in IFNγ-driven sepsis after EMBRACE trial shows proof-of-concept. Find out what this pivot means for its strategy and the field.
Ionis and SOBI’s olezarsen cuts pancreatitis risk by 85% in sHTG phase 3 trials
Olezarsen showed 85% reduction in acute pancreatitis for severe hypertriglyceridemia. See what this means for Sobi, Ionis, and upcoming EMA and FDA filings.
Will NASP transform gout care in 2026? Sobi’s biologic therapy heads for FDA decision
Sobi’s NASP for uncontrolled gout advances to FDA review with June 2026 PDUFA date. Find out how this novel therapy could reshape gout treatment.
Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the…
Sonofi and Sobi get Altuviiio FDA approval to treat hemophilia A
Sonofi and Sobi have secured the approval of the US Food and Drug Administration (FDA) for their Altuviiio…
Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase…